Editas Medicine and Sandhill Therapeutics, Inc. Announce Collaboration to Develop Engineered Cell Medicines to Treat Cancer

NEXT STORY
Turning Point Therapeutics Announces Program Updates and Milestones for 2020
PREV STORY
Delcath Completes Enrollment in its United States Registration Pivotal Trial (FOCUS) Investigating Melphalan/HDS in the Treatment of Patients with Unresectable Hepatic-Dominant Ocular Melanoma
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

ABLYNX TO PRESENT ADDITIONAL DATA FOR ITS ANTI-IL-6R NANOBODY, VOBARILIZUMAB, A POTENTIAL BEST-IN-CLASS TREATMENT FOR RHEUMATOID ARTHRITIS

Data from the Phase IIb study in patients with moderate-to-severe disease already being treated ...

author_avatar
NASDAQ Market News

Affimed Announces FDA Clearance of IND to Commence First-in-Human Phase 1/2a Study of AFM24 for the Treatment of EGFR-Expressing Cancers

author_avatar
NASDAQ Market News

New phase III data shows investigational antibody cocktail casirivimab and imdevimab reduced hospitalisation or death by 70% in non-hospitalised patients with COVID-19

author_avatar
NASDAQ Market News